Translational Lung Cancer Research

Papers
(The H4-Index of Translational Lung Cancer Research is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report89
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors71
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series56
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk49
End-to-side anastomosis in complex tracheal resection and reconstruction: a case series study40
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)37
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network35
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review34
Whole genome characterization of patient-derived lung cancer organoids32
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study31
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer30
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report27
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–203027
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer27
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer26
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer26
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression25
Real-world data on severe lung cancer: a multicenter retrospective study25
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma25
Targeting ferroptosis to overcome drug resistance in lung cancer25
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?24
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study23
Needle tract seeding after endobronchial ultrasound-guided intranodal forceps biopsy and cryobiopsy: a case report23
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety23
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer23
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell23
0.096698045730591